ECL Stock Cash Flow Statements

Ecolab Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Ecolab Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2024-12-31	2024-09-30	2023-12-31	2023-09-30	2022-12-31	2022-09-30	2021-12-31	2021-09-30	2020-12-31	2020-09-30	2019-12-31	2019-09-30	2018-12-31	2018-09-30	2017-12-31	2017-09-30	2016-12-31	2016-09-30


operating activities
net income including noncontrolling interest	479,500,000	740,800,000	410,800,000	409,400,000	269,500,000	352,000,000	305,300,000	328,600,000	304,900,000	249,300,000	434,300,000		400,200,000	438,300,000	571,700,000	395,800,000	372,000,000	379,500,000
adjustments to reconcile net income to cash from operating activities:
depreciation	161,200,000	156,800,000	153,400,000	152,000,000	155,100,000	152,200,000	151,300,000	149,200,000	151,200,000	150,100,000	165,800,000		159,800,000	156,000,000	148,700,000	150,700,000	140,100,000	144,900,000
amortization	74,300,000	73,300,000	77,100,000	77,400,000	81,400,000	80,600,000	64,300,000	57,700,000	56,300,000	58,900,000	79,000,000		78,100,000	78,600,000	79,100,000	77,600,000	72,500,000	71,900,000
deferred income taxes	-40,800,000	-12,000,000	-9,800,000	-9,100,000	-36,000,000	-49,000,000	-53,800,000	13,200,000	-29,200,000	8,400,000	-55,400,000		28,500,000	24,000,000	-364,900,000	24,500,000	-35,300,000	-26,500,000
share-based compensation expense	25,300,000	26,600,000	21,700,000	14,700,000	20,600,000	14,400,000	17,000,000	13,600,000	17,000,000	11,400,000	17,900,000		18,900,000	13,700,000	18,700,000	14,300,000	18,000,000	14,100,000
pension and postretirement plan contributions	-10,700,000	-12,900,000	-17,100,000	-63,200,000	-12,500,000	-16,700,000	-8,900,000	-14,800,000	-20,600,000	-16,000,000	-22,000,000		-14,000,000	-12,000,000	-13,100,000	-94,000,000	-4,800,000	-15,000,000
pension and postretirement plan income	2,800,000	3,500,000	-2,900,000	1,700,000
restructuring charges, net of cash paid	35,400,000	-1,800,000	-15,100,000	8,800,000	84,000,000	-4,400,000	-6,600,000	-19,200,000	17,200,000	13,900,000	4,000,000		-13,900,000	63,700,000	-8,100,000	-7,000,000	-12,400,000	-21,000,000
sale of global surgical solutions business
other	6,600,000	4,100,000	10,800,000	7,900,000	11,700,000	3,100,000	-3,800,000	7,700,000	16,800,000	-9,600,000	5,300,000		4,000,000	7,700,000	17,500,000	7,300,000	2,300,000	-800,000
changes in operating assets and liabilities, net of effect of acquisitions:
accounts receivable	-37,400,000	800,000	4,600,000	-36,100,000	31,200,000	-116,800,000	-77,200,000	-81,900,000	57,100,000	2,400,000	-61,500,000		-2,800,000	-72,800,000	-68,300,000	-39,500,000	-36,900,000	-24,700,000
inventories	48,000,000	-71,300,000	53,900,000	115,500,000	-17,200,000	-134,900,000	6,800,000	23,700,000	-3,400,000	-24,200,000	88,600,000		30,100,000	-52,300,000	31,400,000	-21,100,000	-15,800,000	-6,000,000
other assets	16,800,000	-32,000,000	47,000,000	6,000,000	66,800,000	-301,800,000	-44,800,000	5,700,000	64,700,000	26,900,000	60,700,000		-57,800,000	24,200,000	-57,300,000	18,000,000	-20,900,000	-33,700,000
accounts payable	22,300,000	67,600,000	13,400,000	19,000,000	134,500,000	96,400,000	128,900,000	38,000,000	44,100,000	-8,300,000	11,300,000		61,300,000	-27,600,000	64,100,000	-27,000,000	-17,500,000	41,600,000
other liabilities	-17,600,000	225,900,000	104,700,000	83,700,000	45,100,000	338,400,000	149,900,000	65,500,000	-40,400,000	-99,300,000	80,300,000		126,400,000	16,800,000	252,000,000	76,400,000	-34,700,000	98,000,000
cash from operating activities	766,700,000	786,700,000	852,500,000	787,700,000	859,200,000	436,700,000	640,900,000	622,700,000	649,800,000	451,800,000	821,000,000		827,300,000	664,700,000	646,400,000	585,200,000	448,000,000	616,900,000
investing activities
capital expenditures	-359,700,000	-236,400,000	-262,600,000	-166,500,000	-202,800,000	-192,500,000	-219,200,000	-178,200,000	-126,700,000	-111,700,000	-250,200,000		-213,000,000	-221,600,000	-251,400,000	-198,000,000	-228,800,000	-174,900,000
free cash flows	407,000,000	550,300,000	589,900,000	621,200,000	656,400,000	244,200,000	421,700,000	444,500,000	523,100,000	340,100,000	570,800,000		614,300,000	443,100,000	395,000,000	387,200,000	219,200,000	442,000,000
property and other assets sold	8,000,000	-200,000	400,000	900,000	800,000	700,000	-100,000	12,000,000	2,800,000	800,000	2,400,000		500,000	5,000,000	6,600,000	1,600,000	900,000	18,200,000
acquisitions and investments in affiliates, net of cash acquired	-256,500,000	-17,700,000	-73,600,000	-1,800,000	0	0	-3,713,800,000	-120,100,000	0	-200,000	-4,800,000		-152,200,000	500,000	-158,000,000	-4,700,000	-4,800,000	-35,300,000
divestiture of businesses, net of cash divested	0
cash from investing activities	-627,500,000	639,100,000	-348,400,000	-178,600,000	-210,400,000	-195,600,000	-3,941,200,000	-290,700,000	-61,800,000	-173,800,000	-269,900,000		-381,100,000	-204,500,000	-305,100,000	-218,000,000	-247,700,000	-257,900,000
financing activities
net (repayments) issuances of commercial paper and notes payable			-1,600,000
long-term debt borrowings							2,481,300,000		0	1,087,000,000					814,400,000		1,596,200,000	0
long-term debt repayments	0	-800,000					0		0	-1,270,000,000	0		-249,800,000	-1,200,000	-778,900,000	-14,800,000	-1,439,100,000	-500,000
reacquired shares	-2,800,000	-464,300,000	-2,000,000	-800,000	-72,800,000	-42,600,000	-28,800,000	-7,200,000	-21,600,000	-19,900,000	-5,100,000		-241,000,000	-105,600,000	-12,600,000	-86,600,000	-1,800,000	-99,900,000
dividends paid	-161,400,000	-162,200,000	-154,700,000	-154,000,000	-157,800,000	-144,900,000	-139,900,000	-139,900,000	-139,000,000	-138,600,000	-136,900,000		-125,700,000	-118,500,000	-118,400,000	-107,400,000	-103,000,000	-106,900,000
exercise of employee stock options	26,600,000	78,400,000	35,600,000	10,600,000	8,300,000	8,100,000	49,200,000	53,900,000	41,800,000	11,000,000	15,100,000		28,700,000	35,400,000	20,800,000	8,400,000	14,500,000	21,600,000
hedge settlements	0	0	38,100,000	100,000	62,400,000	54,200,000
cash used provided by financing activities
effect of exchange rate changes on cash and cash equivalents	-3,400,000	-6,400,000	-400,000	-15,000,000	-1,400,000	-5,700,000	-200,000	4,500,000							-16,800,000	7,700,000	-8,700,000	400,000
increase in cash and cash equivalents	-4,300,000		-81,800,000				-538,000,000	-504,500,000							2,300,000	-51,600,000	146,800,000	13,200,000
net change in cash balances classified as assets held for sale
cash and cash equivalents, beginning of period	0	0	0	0	0	0	0	0							0	0	0	0
cash and cash equivalents, end of period	-4,300,000	877,100,000	-81,800,000	447,100,000	485,700,000	-12,000,000	-538,000,000	-504,500,000							2,300,000	-51,600,000	146,800,000	13,200,000
net issuances of commercial paper and notes payable		1,600,000						1,500,000		-288,900,000				-107,000,000
cash from financing activities	-140,100,000	-548,300,000	-585,500,000	-147,000,000	-161,700,000	-247,400,000	2,762,500,000	-841,000,000	-370,500,000	-690,300,000	-502,100,000		-353,200,000	-313,000,000	-322,200,000	-426,500,000	-44,800,000	-346,200,000
decrease in cash and cash equivalents
gain on sale of global surgical solutions business	1,000,000
net issuances (repayments) of commercial paper and notes payable																-722,000,000	-84,000,000	-180,000,000
supplemental cash flow information
income taxes paid
net interest paid
debt refinancing							0		0
less: net income from discontinued operations, including noncontrolling interest
net income from continuing operations, including noncontrolling interest
pension and postretirement plan expense					25,000,000		12,500,000	6,300,000	14,100,000	10,800,000	12,700,000		8,500,000	6,400,000	10,400,000	9,200,000	11,000,000	14,500,000
cash from operating activities - continuing operations							640,900,000	622,700,000	649,800,000	451,800,000
cash from operating activities - discontinued operations									0	0
divestiture of businesses									60,800,000	0	0		0	800,000
cash from investing activities - continuing operations							-3,941,200,000	-290,700,000	-61,800,000	-106,200,000
cash from investing activities - discontinued operations									0	-67,600,000
cash from financing activities - continuing operations							2,762,500,000	-841,000,000	-370,500,000	-690,300,000
cash from financing activities - discontinued operations									0	0
cash and cash equivalents, beginning of period - continuing operations							0	0
cash and cash equivalents, beginning of period - discontinued operations
cash and cash equivalents, end of period - continuing operations							-538,000,000	-504,500,000
cash and cash equivalents, end of period - discontinued operations
net issuances (payments) of commercial paper and notes payable
less: net income from discontinued operations including noncontrolling interest									0	0
net income from continuing operations including noncontrolling interest							305,300,000	328,600,000	304,900,000	249,300,000
effect of exchange rate changes on cash, cash equivalents and restricted cash									8,000,000	10,400,000	1,500,000		-2,600,000	2,200,000
increase in cash, cash equivalents and restricted cash									225,500,000	-401,900,000
cash, cash equivalents and restricted cash, beginning of period - continuing operations									0	0
cash, cash equivalents and restricted cash, beginning of period - discontinued operations									0	0
cash, cash equivalents and restricted cash, beginning of period									0	0	0		0	0
cash, cash equivalents and restricted cash, end of period - continuing operations									225,500,000	-334,300,000
cash, cash equivalents and restricted cash, end of period - discontinued operations
cash, cash equivalents and restricted cash, end of period									225,500,000	-334,300,000	50,500,000		90,400,000	149,400,000
acquisition related liabilities and contingent consideration										-2,600,000	0		100,000	100,000	-300,000	0	-31,700,000	-400,000
gain on sale of businesses
asset charges and write-downs																	15,000,000	0
settlement of net investment hedges													0	0
acquisition of noncontrolling interests
decrease in cash, cash equivalents and restricted cash														149,400,000
excess tax benefits from share-based payment arrangements																	-4,100,000	-19,900,000
interest paid
venezuelan charges
(gain) loss on sale of business
capitalized software expenditures															-23,200,000	-17,800,000	-17,200,000	-10,000,000
release from (deposit into) acquisition related escrow
reduction of cash due to venezuelan deconsolidation
restricted cash activity															0	0	0
net repayments of commercial paper and notes payable
deposit into acquisition related escrow																900,000
release from acquisition related escrow
loss on sale of business
adjustments to reconcile net income including noncontrolling interest to cash from operating activities:
restructuring, net of cash paid
(gain) loss on sale of businesses
fixed asset impairment
cash and cash equivalents, beginning of year
cash and cash equivalents, end of year

We provide you with 20 years of cash flow statements for Ecolab stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Ecolab stock. Explore the full financial landscape of Ecolab stock with our expertly curated income statements.

The information provided in this report about Ecolab stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.